Stock Track | Senseonics Soars on FDA Approval of Game-Changing Eversense 365 CGM System

Stock Track

Sep 17, 2024

Shares of Senseonics Holdings (NYSE: SENS) surged over 6% in pre-market trading on Monday after the company announced that its next-generation Eversense 365 continuous glucose monitoring (CGM) system has received clearance from the U.S. Food and Drug Administration (FDA).

The Eversense 365 is being hailed as a breakthrough in diabetes technology, as it is the world's first CGM system to offer a sensor that can last for one full year - a significant improvement over currently available short-term CGM sensors that need to be replaced every 10-14 days.

With a single sensor insertion, the Eversense 365 system provides people with diabetes an uninterrupted year of glucose monitoring, reducing the burden and inconvenience of frequent sensor changes. Additionally, the system offers seamless device connectivity, high accuracy, and improved discretion with on-body vibration alerts.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1118951277"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118951277\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118951277?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-17 19:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118951277","market":"us","top_or_hot":-1,"title":"Stock Track | Senseonics Soars on FDA Approval of Game-Changing Eversense 365 CGM System","media":"Stock Track","content":"<p>Shares of Senseonics Holdings (NYSE: SENS) surged over 6% in pre-market trading on Monday after the company announced that its next-generation Eversense 365 continuous glucose monitoring (CGM) system has received clearance from the U.S. Food and Drug Administration (FDA).</p>\n\n<p>The Eversense 365 is being hailed as a breakthrough in diabetes technology, as it is the world's first CGM system to offer a sensor that can last for one full year - a significant improvement over currently available short-term CGM sensors that need to be replaced every 10-14 days.</p>\n\n<p>With a single sensor insertion, the Eversense 365 system provides people with diabetes an uninterrupted year of glucose monitoring, reducing the burden and inconvenience of frequent sensor changes. Additionally, the system offers seamless device connectivity, high accuracy, and improved discretion with on-body vibration alerts.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Senseonics Soars on FDA Approval of Game-Changing Eversense 365 CGM System</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Senseonics Soars on FDA Approval of Game-Changing Eversense 365 CGM System\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-09-17 19:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Senseonics Holdings (NYSE: SENS) surged over 6% in pre-market trading on Monday after the company announced that its next-generation Eversense 365 continuous glucose monitoring (CGM) system has received clearance from the U.S. Food and Drug Administration (FDA).</p>\n\n<p>The Eversense 365 is being hailed as a breakthrough in diabetes technology, as it is the world's first CGM system to offer a sensor that can last for one full year - a significant improvement over currently available short-term CGM sensors that need to be replaced every 10-14 days.</p>\n\n<p>With a single sensor insertion, the Eversense 365 system provides people with diabetes an uninterrupted year of glucose monitoring, reducing the burden and inconvenience of frequent sensor changes. Additionally, the system offers seamless device connectivity, high accuracy, and improved discretion with on-body vibration alerts.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SENS","symbol_name":"Senseonics Holdings,Inc.","start_time":0,"source_url":"","article_id":"1118951277","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118951277","pubTimestamp":1726571194,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Senseonics Holdings  surged over 6% in pre-market trading on Monday after the company announced that its next-generation Eversense 365 continuous glucose monitoring  system has received clearance from the U.S. Food and Drug Administration .The Eversense 365 is being hailed as a breakthrough in diabetes technology, as it is the world's first CGM system to offer a sensor that can last for one full year - a significant improvement over currently available short-term CGM sensors that need ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SENS":"Senseonics Holdings,Inc."},"translate_title":"FDA批准改变游戏规则的Eversense 365 CGM系统后，Senseonics股价飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SENS":1},"content_text":"Shares of Senseonics Holdings (NYSE: SENS) surged over 6% in pre-market trading on Monday after the company announced that its next-generation Eversense 365 continuous glucose monitoring (CGM) system has received clearance from the U.S. Food and Drug Administration (FDA).\nThe Eversense 365 is being hailed as a breakthrough in diabetes technology, as it is the world's first CGM system to offer a sensor that can last for one full year - a significant improvement over currently available short-term CGM sensors that need to be replaced every 10-14 days.\nWith a single sensor insertion, the Eversense 365 system provides people with diabetes an uninterrupted year of glucose monitoring, reducing the burden and inconvenience of frequent sensor changes. Additionally, the system offers seamless device connectivity, high accuracy, and improved discretion with on-body vibration alerts.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}